IVPost
NIH renews NeuroNEXT for neurological clinical research
- Details
- Written by Barbara McMakin
- Category: Latest News
Washington, DC - The Network for Excellence in Neuroscience Clinical Trials, or NeuroNEXT, a research program that helps streamline Phase II clinical trials for brain disorders, has been renewed for five more years, with several new centers joining the program. NeuroNEXT is supported by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health.
NIH expands program that conducts large-scale clinical trials in real-world settings
- Details
- Written by IVPost
- Category: Health News
Washington, DC - The National Institutes of Health’s Health Care Systems (HCS) Research Collaboratory, which involves health care systems in conducting large-scale clinical studies, has announced five new research awards — totaling $4.15 million for a one-year planning phase, with an estimated $30.85 million expected for four subsequent years of study implementation. The HCS Research Collaboratory was developed by the NIH Common Fund in 2012 and is administered by the National Center for Complementary and Integrative Health (NCCIH) and the National Institute on Aging (NIA).
New materials improve delivery of therapeutic messenger RNA
- Details
- Written by Anne Trafton
- Category: Latest News
Cambridge, Massachusetts - In an advance that could lead to new treatments for a variety of diseases, MIT researchers have devised a new way to deliver messenger RNA (mRNA) into cells.
Sound researcher receives highest honor for decades of work in hearing science
- Details
- Written by IVP
- Category: Health News
Tempe, Arizona - We learn the basics of hearing sound waves, ear parts, and the effects of pitch and volume sometime around third grade, but there are still mysteries to unravel, including how we process where sounds are located, especially if there are a lot of different sounds at one time, or how we handle sounds that are moving.
FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation
- Details
- Written by Sandy Walsh
- Category: Latest News
Washington, DC - The U.S. Food and Drug Administration approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. This is the first drug in its class (IDH1 inhibitors) and is approved for use with an FDA-approved companion diagnostic used to detect specific mutations in the IDH1 gene in patients with AML.
FDA approves first cancer drug through new oncology review pilot that enables greater development efficiency
- Details
- Written by IVPost
- Category: Medical News
Washington, DC - The U.S. Food and Drug Administration approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy. The FDA also approved Kisqali in combination with fulvestrant for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.
Page 3 of 50